Dementia with Lewy Bodies Drug Therapies in Clinical Trials: Systematic Review up to 2022.

ABSTRACT:

Introduction

Reviews of randomized clinical trials (RCTs) in dementia with Lewy bodies (DLB) are essential for informing ongoing research efforts of symptomatic therapies and potentially disease-modifying therapies (DMTs).

Methods

We performed a systematic review of all clinical trials conducted until September 27, 2022, by examining 3 international registries: ClinicalTrials.gov, the European Union Drug Regulating Authorities Clinical Trials Database, and the International Clinical Trials Registry Platform, to identify drugs in trials in DLB.

Results

We found 25 agents in 40 trials assessing symptomatic treatments and DMTs for DLB: 7 phase 3, 31 phase 2, and 2 phase 1 trials. We found an active pipeline for drug development in DLB, with most ongoing clinical trials i

SUBMITTER: Abdelnour C 

PROVIDER: S-EPMC10195935 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature